RxDoctor Payments Data

Saundra Anderson, DO

Family Medicine · Yoakum, TXNPI 1861553067

Payments from drug & device makers

$2,898in general payments, 2019–2025

Across 182 payments — averaging $15.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$651
  • Merck$302
  • Johnson & Johnson$212
  • AbbVie$201
  • Astellas Pharma US Inc$190
  • Lilly USA, LLC$188
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$2,79997%
  • Education$993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,898 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$179,660
Medicare patients
331
Services billed
4,737

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide93$102,935
EliquisApixaban115$80,938
JardianceEmpagliflozin70$44,989
TrulicityDulaglutide44$42,369
RexultiBrexpiprazole23$32,837
MyrbetriqMirabegron64$31,524
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$30,918
JanuviaSitagliptin Phosphate43$27,240
FarxigaDapagliflozin Propanediol44$26,051
XareltoRivaroxaban44$23,051
LinzessLinaclotide22$11,413
Repatha SureclickEvolocumab14$10,653
Tresiba Flextouch U-100Insulin Degludec11$7,721
Lantus SolostarInsulin Glargine,hum.Rec.Anlog45$7,186
Humalog Kwikpen U-100Insulin Lispro18$5,740

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$651$102,93593 claims
PfizerEliquis$63$80,938115 claims
Lilly USA, LLCTrulicity$188$42,36944 claims
Otsuka America Pharmaceutical, Inc.Rexulti$164$32,83723 claims
Astellas Pharma US IncMyrbetriq$190$31,52464 claims
GSKTrelegy Ellipta$13$30,91830 claims
MerckJanuvia$302$27,24043 claims
AstraZenecaFarxiga$113$26,05144 claims
Johnson & JohnsonXarelto$212$23,05144 claims
AbbVieLinzess, Synthroid$201$13,54651 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Yoakum

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →